Blueprint Medicines Corp
NASDAQ:BPMC

Watchlist Manager
Blueprint Medicines Corp Logo
Blueprint Medicines Corp
NASDAQ:BPMC
Watchlist
Price: 127.85 USD -0.09%
Market Cap: 8.3B USD

Relative Value

The Relative Value of one BPMC stock under the Base Case scenario is 179.08 USD. Compared to the current market price of 127.85 USD, Blueprint Medicines Corp is Undervalued by 29%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BPMC Relative Value
Base Case
179.08 USD
Undervaluation 29%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
47
vs Industry
40
Median 3Y
14.5
Median 5Y
14.5
Industry
7.1
Forward
11.2
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-6.9
Industry
23
Forward
-133.9
vs History
vs Industry
Median 3Y
-11.4
Median 5Y
-11.2
Industry
19.4
vs History
vs Industry
Median 3Y
-12.4
Median 5Y
-11.2
Industry
23.1
vs History
4
vs Industry
4
Median 3Y
18
Median 5Y
6.5
Industry
2.6
vs History
41
vs Industry
34
Median 3Y
12.5
Median 5Y
12.5
Industry
7.5
Forward
10.9
vs History
41
vs Industry
35
Median 3Y
13.6
Median 5Y
13.6
Industry
9.4
vs History
vs Industry
Median 3Y
-7.5
Median 5Y
-6.3
Industry
4.4
Forward
-96.6
vs History
vs Industry
Median 3Y
-7.3
Median 5Y
-6.1
Industry
4.5
Forward
-100.9
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-9.5
Industry
5.2
vs History
vs Industry
Median 3Y
-9.7
Median 5Y
-9.1
Industry
3.7
vs History
14
vs Industry
19
Median 3Y
9.5
Median 5Y
7.6
Industry
4.8

Multiples Across Competitors

BPMC Competitors Multiples
Blueprint Medicines Corp Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Blueprint Medicines Corp
NASDAQ:BPMC
8.3B USD 14.7 -53 -50.7 -46.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 706 638.2 -164 955.5 -200 308.6 -198 022.8
US
Abbvie Inc
NYSE:ABBV
335B USD 5.8 80.7 15.3 22.7
US
Amgen Inc
NASDAQ:AMGN
158.5B USD 4.6 26.7 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
138.1B USD 4.8 23.1 10.1 13.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 10.4 -116.9 24.7 25.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 029.8 -518 -564 -549
AU
CSL Ltd
ASX:CSL
118.2B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.5B USD 4 12.6 11.1 12.5
US
Seagen Inc
F:SGT
39.3B EUR 19.6 -60 -64.6 -58.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.7B USD 16.9 -147.1 -658.4 -329.9
P/E Multiple
Earnings Growth PEG
US
Blueprint Medicines Corp
NASDAQ:BPMC
Average P/E: 34.2
Negative Multiple: -53
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -164 955.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.7
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.7
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.1
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -518 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -147.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Blueprint Medicines Corp
NASDAQ:BPMC
Average EV/EBITDA: 15.5
Negative Multiple: -50.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 308.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -658.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Blueprint Medicines Corp
NASDAQ:BPMC
Average EV/EBIT: 20
Negative Multiple: -46.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 022.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -549 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -329.9 N/A N/A